<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14116">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923115</url>
  </required_header>
  <id_info>
    <org_study_id>DS1040-B-U107</org_study_id>
    <secondary_id>2015-005211-32</secondary_id>
    <nct_id>NCT02923115</nct_id>
  </id_info>
  <brief_title>Randomized Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism</brief_title>
  <official_title>A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b When Added to Standard of Care Anticoagulation Therapy in Subjects With Acute Submassive Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Trial Expertise and Advisory Servies (ITREAS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b, double-blind (Principal Investigators, study subjects, Sponsor, Academic
      Research Organization ARO and Clinical Research Organization CRO blinded),
      placebo-controlled, randomized, single-ascending dose, multi-center study to assess the
      safety, efficacy, tolerability, pharmacokinetics PK, and pharmacodynamics PD of DS-1040b in
      subjects with acute submassive pulmonary embolism.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of adjudicated clinically relevant bleeding, compared to placebo</measure>
    <time_frame>baseline Day 0 to Day 30</time_frame>
    <description>To assess the safety and tolerability of ascending doses of DS-1040b given as a single intravenous (IV) infusion, when added to standard of care (SOC) anticoagulation therapy, by evaluating the rate of adjudicated clinically relevant bleeding, compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary embolism PE thrombus volume reduction</measure>
    <time_frame>baseline Day 0 to Day 30</time_frame>
    <description>PE thrombus volume reduction from baseline to end of study drug administration assessed via CT pulmonary angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of serious adverse events</measure>
    <time_frame>baseline Day 0 to Day 30</time_frame>
    <description>Overall safety evaluation (serious adverse events [SAEs], treatment-emergent adverse events [TEAEs], clinical laboratory parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of treatment emergent adverse events</measure>
    <time_frame>baseline Day 0 to Day 30</time_frame>
    <description>Overall safety evaluation (serious adverse events [SAEs], treatment-emergent adverse events [TEAEs], clinical laboratory parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of clinical laboratory abnormalities</measure>
    <time_frame>baseline Day 0 to Day 30</time_frame>
    <description>Overall safety evaluation (serious adverse events [SAEs], treatment-emergent adverse events [TEAEs], clinical laboratory parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Curve (AUC)</measure>
    <time_frame>baseline Day 0 to Day 30</time_frame>
    <description>Pharmacokinetics (PK) of DS-1040b in subjects with PE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2)</measure>
    <time_frame>baseline Day 0 to Day 30</time_frame>
    <description>Pharmacokinetics (PK) of DS-1040b in subjects with PE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>baseline Day 0 to Day 30</time_frame>
    <description>Pharmacokinetics (PK) of DS-1040b in subjects with PE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration (Tmax)</measure>
    <time_frame>baseline Day 0 to Day 30</time_frame>
    <description>Pharmacokinetics (PK) of DS-1040b in subjects with PE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Pulmonary Embolism</condition>
  <condition>Thrombotic Disease</condition>
  <arm_group>
    <arm_group_label>DS-1040b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 subjects each in Cohorts 1 and 2, and 15 subjects each in Cohorts 3, 4, 5, and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>9 subjects each in Cohorts 1 and 2, and 5 subjects each in Cohorts 3, 4, 5, and 6.
0.9% Sodium Chloride Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-1040b</intervention_name>
    <description>injection</description>
    <arm_group_label>DS-1040b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>0.9% Sodium Chloride Injection</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects, age 18 to 75 years admitted to hospital with a clinical
             diagnosis of acute PE categorized as low risk or intermediate-risk or submassive PE
             and for whom catheter-based therapy is not planned;

          -  Subjects must have a CTA scan confirming the PE diagnosis and with at least one
             measurable index lesion in a segmental or larger pulmonary artery prior to
             randomization;

          -  Subjects should be in otherwise satisfactory health in the opinion of the
             Investigator;

          -  Subjects must be able to provide written informed consent.

        Exclusion Criteria:

          -  Subjects with acute PE categorized as high-risk or massive, or who are
             hemodynamically unstable, evidenced by a heart rate &gt; 120 /min and a systolic blood
             pressure (SBP) of &lt; 90 mmHg for more than 15 consecutive minutes or a drop in SBP of
             &gt; 40 mmHg since presentation;

          -  Subjects for whom use of a thrombolytic, either systemic or via catheter, is planned;

          -  Subjects with PE lesions only in the sub-segmental or smaller arteries;

          -  Subjects receiving any vitamin K antagonists (VKAs) prior to randomization or
             receiving more than 36 hours treatment with LMW(low molecular weight Heparin) in
             therapeutic doses prior to randomization;

          -  Subjects who had a prior intracranial hemorrhage, known arteriovenous malformation or
             aneurysm, head trauma, or evidence of active bleeding;

          -  Subjects who within 48 hours of randomization have used an anti-Factor IIa agent such
             as dabigatran or an anti-FXa agent such as rivaroxaban, apixaban, or edoxaban;

          -  Subjects who within 21 days prior to randomization have had gastrointestinal or
             genitourinary bleeding;

          -  Subjects who within 14 days prior to randomization have had major surgery or a lumbar
             puncture (or epidural steroid injection);

          -  Subjects with diagnosed active liver disease or with elevation of liver
             enzymes/bilirubin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Indravadan (Indu) Patel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medpace</last_name>
    <phone>866-872-2349</phone>
    <email>recruitment@medpace.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Intercoastal Medical Group</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercury Street Medical</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Radiology Associate</name>
      <address>
        <city>New York City,</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Capital Area Research</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universite Libre de Bruxelles (ULB) - Hopital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Brest - Hopital de la Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Gabriel Montpied Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75017</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU St Etienne - Hopital Nord</name>
      <address>
        <city>Saint-étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Civil de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU Ospedali Riuniti di Ancona</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitá di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Poliambulanza Istituto Ospedaliero</name>
      <address>
        <city>Brescia</city>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universit degli Studi di Perugia - Azienda Ospedaliera di Perugia</name>
      <address>
        <city>Perugia</city>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Noordwest Ziekenhuisgroep</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Hospital</name>
      <address>
        <city>Dordrecht</city>
        <zip>3318 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center - Leids Universitair Medisch Centrum (LUMC)</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Seville</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 4, 2017</lastchanged_date>
  <firstreceived_date>September 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venous thromboembolism</keyword>
  <keyword>VTE</keyword>
  <keyword>Pulmonary embolism</keyword>
  <keyword>PE</keyword>
  <keyword>Acute Submassive Pulmonary Embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
